New cocktail aims to stall breast cancer spread in Hard-to-Treat cases
NCT ID NCT07467330
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding a chemotherapy drug (capecitabine) to a standard two-drug regimen (dalpiciclib plus hormone therapy) can slow cancer growth longer in people with HR+/HER2- breast cancer that has spread to internal organs. About 258 participants will be randomly assigned to either the three-drug combo or the two-drug combo. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dalpiciclib, capecitabine, and endocrine therapy (aromatase inhibitor or fulvestrant)
What this could lead to
If successful, this could offer a new treatment option that delays cancer progression for people with HR+/HER2- breast cancer that has spread to organs.
What could go wrong
This is an early-stage Phase 3 trial with 258 participants, so results may not apply to everyone. Adding capecitabine may increase side effects like hand-foot syndrome or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hosptial
RECRUITINGFuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••